Cargando…

HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma

Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ying, Liu, Zhuogang, Wang, Hongtao, Zhang, Guojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219970/
https://www.ncbi.nlm.nih.gov/pubmed/34178656
http://dx.doi.org/10.3389/fonc.2021.670673
_version_ 1783711055891922944
author Yang, Ying
Liu, Zhuogang
Wang, Hongtao
Zhang, Guojun
author_facet Yang, Ying
Liu, Zhuogang
Wang, Hongtao
Zhang, Guojun
author_sort Yang, Ying
collection PubMed
description Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression, we further stratified MM patients into high and low-expression groups, and then found high expression of HLA-E was correlated with advanced ISS stage (p = 0.025) and high-risk cytogenetics risk stratification (p = 0.000) by the Pearson Chi-square test, suggesting that HLA-E could be considered as a biomarker for high-risk MM. Furthermore, peptide 3 (P3) from our previous study was confirmed to possess a high affinity to HLA-E positive MM cells. Taken together, HLA-E could be considered as a new marker and candidate treatment target for MM, while peptide P3 may act as a potential treatment choice for targeting MM cells.
format Online
Article
Text
id pubmed-8219970
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82199702021-06-24 HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma Yang, Ying Liu, Zhuogang Wang, Hongtao Zhang, Guojun Front Oncol Oncology Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression, we further stratified MM patients into high and low-expression groups, and then found high expression of HLA-E was correlated with advanced ISS stage (p = 0.025) and high-risk cytogenetics risk stratification (p = 0.000) by the Pearson Chi-square test, suggesting that HLA-E could be considered as a biomarker for high-risk MM. Furthermore, peptide 3 (P3) from our previous study was confirmed to possess a high affinity to HLA-E positive MM cells. Taken together, HLA-E could be considered as a new marker and candidate treatment target for MM, while peptide P3 may act as a potential treatment choice for targeting MM cells. Frontiers Media S.A. 2021-06-09 /pmc/articles/PMC8219970/ /pubmed/34178656 http://dx.doi.org/10.3389/fonc.2021.670673 Text en Copyright © 2021 Yang, Liu, Wang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Ying
Liu, Zhuogang
Wang, Hongtao
Zhang, Guojun
HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
title HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
title_full HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
title_fullStr HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
title_full_unstemmed HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
title_short HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
title_sort hla-e binding peptide as a potential therapeutic candidate for high-risk multiple myeloma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219970/
https://www.ncbi.nlm.nih.gov/pubmed/34178656
http://dx.doi.org/10.3389/fonc.2021.670673
work_keys_str_mv AT yangying hlaebindingpeptideasapotentialtherapeuticcandidateforhighriskmultiplemyeloma
AT liuzhuogang hlaebindingpeptideasapotentialtherapeuticcandidateforhighriskmultiplemyeloma
AT wanghongtao hlaebindingpeptideasapotentialtherapeuticcandidateforhighriskmultiplemyeloma
AT zhangguojun hlaebindingpeptideasapotentialtherapeuticcandidateforhighriskmultiplemyeloma